the aid library

LIST OPTIONS

Filter

6851

How can financial risk protection be expanded in Myanmar?

Phone Myint; Than Tun Sein; Cassels, Andrew World Health Organization (WHO) (2015) C_WHO

Policy Note #4: Myanmar Health Systems in Transition Policy Notes Series
Protecting people from financial hardship when they fall ill is one of the two key elements of universal health coverage... more

Addressing non communicable diseases in the COVID-19 response

World Health Organization WHO (2020) C_WHO

People with underlying noncommunicable diseases (NCDs) such as hypertension, diabetes, cardiovascular disease, chronic respiratory disease and cancer have a high risk for developing severe and even fatal COVID-19. It is important for them to strictly follow basic protective measures and make sure th... more

ChAdOx1-S [recombinant], COVID-19 vaccine

World Health Organization WHO (2021) C_WHO

Manufacturers: SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)] Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir... more

Safety surveillance of COVID-19 vaccines in pregnant and breastfeeding women

World Health Organization WHO (2021) C_WHO

COVID-19 Vaccines: 1 Safety Surveillance 2 Manual While there is no indication that pregnant women have an increased susceptibility to infection with SARS-CoV-2, there is evidence that pregnancy may increase the risk of severe illness and mortality from COVID-19 disease in comparison with non-pregn... more

AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine

World Health Organization WHO (2021) C_WHO

10 May 2021. Manufactureres: SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)] The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto... more

External Link

The Alliance of Nurses for Healthy Environments - Website

Climate for Health (2021) CC

The Alliance of Nurses for Healthy Environments (ANHE) is a network of nurses from around the country (and world) who are acting on the notion that our environment and health are inextricably connected. ANHE is a group of nurses from all walks of ou... more

External Link

Vaccines/COVID-19 vaccine EUL issued

World Health Organization WHO (2022) C_WHO

This chronology of facts has challenged public health systems worldwide and regulatory bodies are no exception. Regulatory authorities with mechanisms in place to authorize the use of investigational products had to development guidelines and proced... more

Download (169)

View PDF (148)

WHO advisory committee on variola virus research: report of the twenty-third meeting, virtual meeting, 3-4 November 2021

World Health Organization (WHO) (2021) C_WHO

The Committee discussed the implications for preparedness for smallpox-like events reflected by the ongoing COVID-19 pandemic. The Committee noted how quickly diagnostics and vaccines could be developed and deployed when resources and political will were abundant. This rapidity was also due to the f... more

Download (342)

View PDF (231)

Guidelines for the Clinical Diagnosis and Treatment of Dengue, Chikungunya, and Zika

Pan American Health Organisation PAHO (2022) C_WHO

Evidence-based guidelines are one of the most useful tools for improving public health and clinical practice. Their purpose is to formulate interventions based on strong evidence of efficacy, avoid unnecessary ..., use resources efficiently, reduce clinical variability and, in essence, improve health and ensure quality care, which is the purpose of health systems and services. These guidelines were developed following the GRADE methodology, with the support of a panel of clinical experts from different countries, all convened by the Pan American Health Organization. By responding to twelve key questions about the clinical diagnosis and treatment of dengue, chikungunya, and Zika, evidence-based recommendations were formulated for pediatric, youth, adult, older adult, and pregnant patients who are exposed to these diseases or have a suspected or confirmed diagnosis of infection. The purpose of the guidelines is to prevent progression to severe forms of these diseases and the fatal events they may cause. The recommendations are intended for health professionals, including general, resident, and specialist physicians, nursing professionals, and medical and nursing students, who participate in caring for patients with suspected dengue, chikungunya, or Zika. They are also intended for health unit managers and the executive teams of national arboviral disease prevention and control programs, who are responsible for facilitating the process of implementing these guidelines. more

External Link

The Road to 2030 - Advocacy brief: Progress and challenges

World Health Organization WHO Team Control of Neglected Tropical Diseases (2022) C_WHO

In January 2021, the World Health Organization (WHO) published a new road map to address the burden of disease and death imposed by neglected tropical diseases (NTDs). The end of the first year of the 2021-2030 NTD road map is an opportunity to take... more

Download (135)

View PDF (206)

Preparedness for cyclones, tropical storms, tornadoes, floods and earthquakes during the COVID-19 pandemic

World Health Organisation (WHO) (2023) C_WHO

The WHO health advisory provides guidance to countries on adapting all existing preparedness and response plans and procedures for natural hazards such as cyclones, tropical storms, tornadoes, floods, earthquakes and potential outbreaks of other dis... more

External Link (293)

The generic all-hazards risk assessment and planning tool for mass gathering events

World Health Organisation (WHO) (2023) C_WHO

The Generic All-Hazards Risk Assessment and Planning Tool for Mass Gathering Events (“All-Hazards MG RA Tool”) aims to support Member States and mass gathering events organizers. The tool is based on the principles of the World Health Organiz... more

Download (289)

View PDF (385)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

https://iris.who.int/bitstream/handle/10665/375911/9789290211099-eng.pdf?sequence=1&isAllowed=y

World Health Organization WHO (2024) C_WHO

Food inspection is crucial for ensuring food safety, using risk-based approaches to target high-risk products and businesses. This guidance aids national authorities in designing and implementing risk-based systems, offering step-by-step instructions, examples, and tools for prioritization and inspe... more

Biennium Report 2022–2023 Department of Healthier Populations and Noncommunicable Diseases (HPN)

World Health Organization WHO (2024) C_WHO

Human health and well-being are intimately linked to the state of the environment. Water, sanitation and hygiene (WASH), climate change, air pollution and exposure to hazardous chemicals are major causes of environment-related burden of disease acro... more

Alcohol use

Institute for Health Metrics and Evaluation (2024) CC

The IHME webpage discusses alcohol use as a significant global health risk, responsible for over 1.8 million deaths annually. It highlights age-related differences in alcohol's health impacts, with ... more

Medical device donations: considerations for solicitation and provision. Second edition

World Health Organization WHO (2024) CC

Medical devices are used for the prevention, diagnosis and treatment of illness and diseases and for rehabilitation. WHO developed guidance on medical device donation in 2011, which has been now reviewed, with new evidence, new references on considerations for medical device solicitation and provisi... more

Annual Report: Global Polio Eradication Initiative

World Health Organisation (WHO) (2024) CC

The key to a lasting world free of all forms of poliovirus lies in rapidly interrupting all remaining endemic transmission of WPV in the endemic areas of Pakistan and Afghanistan. This is the only way to ensure that such strains do not re-emerge globally through international spread. It lays the cor... more

External Link

EpiSouth

Network for the Control of Public Health Threats in the Mediterranean Region and South East Europe European Union (2015) CC

EpiSouth Network, established among countries of South-East Europe, North Africa and Middle-East to create a framework of collaboration on epidemiological issues for enhancing communicable diseases surveillance and control of public health ... through communication, training, information exchange and technical support to countries in the Mediterranean region. more

Download (383)

View PDF (550)

Rwanda: MEDICAL WASTE MANAGEMENT PLAN (MWMP)

Ministry of Health, Rwanda (2017) C2

Prepared for the Stunting Prevention and Reduction Project - The project Medical Waste Management Plan’s (MWMP) overall objective is to prevent and/or mitigate the negative effects of increased generation of medical waste on human health and the e... more